

October 30, 2017

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir,

Sub: Board Meeting to consider the Un-audited Financial Results of the Company for the Second Quarter & Half Year ended 30th September, 2017 and the Proposal of payment of Interim Dividend.


We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a Meeting of the Board of Directors of the Company will be held on **Thursday 9th November, 2017** to consider and approve, inter alia, the Un-audited Financial Results of the Company for the second quarter and half year ended 30th September, 2017 and also to consider interim dividend, if any, for the financial year 2017-18.

Further to our letter dated 25th October, 2017 informing the closure of Trading Window of the Company from 28th October, 2017 until 48 hours from the date of declaration of the Un-audited Financial Results of the Company for the second quarter and half year ended 30th September, 2017, we would like to inform you that the Trading Window will be closed up to 11th November, 2017 and shall be re-opened on 12th November, 2017.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED


B. Adi Reddy
Company Secretary

